Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
LQWD Technologies Lightning Network Infrastructure Surpasses 1 Million Global Transactions (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Revive Therapeutics Ltd C.RVV

Alternate Symbol(s):  RVVTF

Healthcare
Revive Therapeutics Ltd. is a Canada-based life sciences company. The Company is focused on the research and development of therapeutics and diagnostics for infectious diseases, medical countermeasures, and rare disorders. It is engaged in exploring the use of Bucillamine for the potential treatment of nerve agent exposure and long COVID. The Company, through its diagnostics division, is... see more

Recent & Breaking News (CSE:RVV)

PharmaTher Provides Business Highlights and Releases Annual Financials for Fiscal Year Ended May 31, 2021

GlobeNewswire September 7, 2021

Revive Therapeutics Signs Exclusive Worldwide License Agreement For Medicinal Mushroom Ganoderma Lucidum To Treat Cancer

GlobeNewswire August 17, 2021

Revive Confirms No Material Undisclosed Information

GlobeNewswire August 12, 2021

Revive Therapeutics Provides Update on Psychedelics Clinical Product Pipeline

GlobeNewswire August 10, 2021

IIROC Trade Resumption - RVV

PR Newswire July 15, 2021

Revive Therapeutics Provides Update on FDA Phase 3 Clinical Trial for Bucillamine in COVID-19

GlobeNewswire July 15, 2021

IIROC Trading Halt - RVV

PR Newswire July 15, 2021

Revive Therapeutics Approved to Trade on the OTCQB Market

GlobeNewswire June 25, 2021

Revive Collaborates With University of Health Sciences Antigua To Pioneer Clinical Research of Psychedelics

GlobeNewswire June 17, 2021

Revive To Present at the H.C. Wainwright Psychedelics in Psychiatry and Beyond Virtual Conference

GlobeNewswire June 14, 2021

Revive Therapeutics (CSE:RVV) partners with Supriya Lifescience to treat COVID-19 in India

Trevor Abes  June 8, 2021

Revive Therapeutics Partners with Supriya to Pursue EUA for Bucillamine to Treat COVID in India

GlobeNewswire June 8, 2021

Revive Therapeutics Enters into Feasibility Agreement with LTS Lohmann to Develop Oral Psilocybin Thin Film Strip

GlobeNewswire May 17, 2021

IIROC Trade Resumption - RVV

Canada NewsWire May 3, 2021

Revive Therapeutics Enters Into Research Agreement with UCSF For Bucillamine As Potential Treatment For Severe COVID-19

GlobeNewswire May 3, 2021

IIROC Trading Halt - RVV

Canada NewsWire May 3, 2021

Psilocybin May Be Helpful for Those with Traumatic Brain Injury

Press Releases April 27, 2021

Revive Therapeutics Files for FDA Orphan Drug Designation for Psilocybin in Traumatic Brain Injury

GlobeNewswire April 27, 2021

PharmaTher Expands Patent Portfolio with Filing of U.S. Patent Application for Ketamine and Repurposing of Psychedelics with panaceAI(TM)

GlobeNewswire April 27, 2021

Revive Therapeutics Announces Successful Research Results for Oral Thin Film Psilocybin and Filing of U.S. Provisional Patent Application

GlobeNewswire April 22, 2021